可溶性ST2通过IGF2R-YY1线粒体轴驱动暴发性心肌炎进展
该研究在柯萨奇病毒B3诱导的暴发性心肌炎(FM)小鼠模型中发现,sST2主要来源于浸润的CCR2+巨噬细胞,通过IGF2R进入心肌细胞并结合YY1,抑制线粒体电子传递链基因表达、减少ATP合成,从而加重心脏损伤。中和sST2抗体可恢复线粒体功能、改善血流动力学并降低死亡率,且与糖皮质激素联用有叠加获益。临床队列中,血浆sST2独立预测FM患者30天死亡或ECMO需求,预后判别优于NT-proBNP和cTnI。
要点
- sST2是FM的预后生物标志物,独立预测30天死亡或ECMO需求。
- sST2通过IGF2R-YY1轴损害心肌细胞线粒体功能,不依赖IL-33。
- 中和sST2抗体可改善线粒体功能、血流动力学并降低死亡率。
核心结论
- sST2通过不依赖IL-33的机制破坏心肌细胞线粒体稳态驱动FM,既是临床预后标志物也是治疗靶点。
研究设计与样本
- 采用柯萨奇病毒B3诱导的FM小鼠模型,结合组织学、分子及单细胞/单核转录组分析。
- 在新生小鼠心肌细胞和人工程心脏组织中评估心肌细胞反应。
- 体内评估sST2中和抗体的疗效与安全性,并在FM患者队列中检验临床相关性。
主要发现
- sST2主要来源于FM心脏中浸润的CCR2+巨噬细胞,加重炎症、线粒体功能障碍和收缩衰竭。
- sST2经IGF2R进入心肌细胞,结合YY1阻止其核转位,抑制线粒体电子传递链基因表达,减少ATP合成。
- 中和sST2抗体恢复线粒体功能、改善血流动力学、降低死亡率,无短期全身毒性。
- 单细胞/单核转录组显示对心肌细胞、成纤维细胞、内皮细胞和巨噬细胞有广泛治疗效应。
- 糖皮质激素与抗sST2联合治疗提供叠加获益。
关键数值与推荐
- 血浆sST2升高独立预测FM患者30天死亡或ECMO需求,预后判别优于NT-proBNP和心脏肌钙蛋白I。
临床怎么用
- 血浆sST2可用于FM患者风险分层,预测30天死亡或ECMO需求。
- sST2中和抗体联合糖皮质激素可能成为FM的候选治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Fulminant myocarditis (FM) is a life-threatening inflammatory cardiomyopathy with high mortality. Soluble ST2 (sST2), traditionally regarded as a decoy receptor for interleukin-33 (IL-33), is markedly elevated in FM, yet its mechanistic and translational roles remain unclear. METHODS: A Coxsackievirus B3-induced FM mouse model was used to define the cellular source and function of sST2 through histological, molecular, and integrated single-cell and single-nucleus transcriptomic analyses. Cardiomyocyte responses were assessed in neonatal murine cardiomyocytes and human engineered heart tissues. The therapeutic efficacy and safety of sST2-neutralizing antibodies were evaluated in vivo, with clinical relevance examined in a cohort of FM patients. RESULTS: sST2 originated predominantly from infiltrating CCR2+ macrophages in FM hearts and aggravated cardiac damage by amplifying inflammation, mitochondrial dysfunction, and contractile failure. Mechanistically, sST2 acted independently of IL-33. It entered cardiomyocytes via IGF2R and bound the transcription factor YY1, preventing its nuclear translocation and repressing mitochondrial electron transport chain gene expression, thereby reducing ATP synthesis. Neutralizing antibodies targeting sST2 effectively restored mitochondrial function, improved hemodynamics, and reduced mortality without evident short-term systemic toxicity. Integrated single-cell and single-nucleus transcriptomic analyses revealed broad therapeutic effects across cardiomyocytes, fibroblasts, endothelial cells, and macrophages. Combined glucocorticoid and anti-sST2 therapy provided additive benefit. Clinically, elevated plasma sST2 independently predicted 30-day mortality or extracorporeal membrane oxygenation requirement in FM patients, outperforming N-terminal pro-B-type natriuretic peptide and cardiac troponin I for prognostic discrimination. CONCLUSIONS: sST2 drives FM by disrupting cardiomyocyte mitochondrial homeostasis independently of IL-33 and represents both a clinically prognostic biomarker and a therapeutic target.
引用
- Zhuang Y, Zhang Z, Li H, et al. Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis. Eur Heart J. 2026. PMID: 41684269. doi:10.1093/eurheartj/ehag105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。